Abstracts
Programme at a glance
  

Thursday  Friday   Saturday  Sunday  Monday

SYMPOSIUM 5

HORMONES

Chairs: S. Adami (Verona, Italy)
E. Wagner (Vienna, Austria)

09:00 I-22 Role of the PTH/PTHrP receptor in bone growth and remodelling
E. Schipani (Boston MA, USA)

09:30 I-23 Role of PTH in the pathogenesis and treatment of osteoporosis
R. Lindsay (New York NY, USA)

HORMONES

Chairs: S. Adami (Verona, Italy)
E. Wagner (Vienna, Austria)

10:00 O-31 PARATHYROID HORMONE EXERTS ANABOLIC EFFECTS ON HUMAN BONE MARROW MESENCHYMAL STEM CELLS
C. Clausen*, B. M. Abdallah, M. Kassem
Department of Endocrinology, Odense University Hospital, Odense, Denmark

10:12 O-32 TERIPARATIDE INCREASES THE WIDTH OF MODELING AND REMODELING OSTEONS AT THE TRABECULAR AND ENDOSTEAL ENVELOPE
E. F. Eriksen*, D. W. Donley, Y. L. Ma
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA

10:24 O-33 GENE EXPRESSION ANALYSIS OF WILD TYPE AND VDR KO-MICE CHALLENGED WITH 1ALPHA,25-DIHYDROXY-VITAMIN D3 AND 24R,25-DIHYDROXY-VITAMIN D3
R. Scott¹, H. L. Henry², M. Heim¹, J. E. Bishop², T. Pennimpede¹, G. Kampmann¹, W. Hunziker¹, P. Weber¹, A. W. Norman², I. Bendik¹*
¹Roche Vitamins Ltd, Research and Development, Human Nutrition & Health, Basel, Switzerland
²University of California, Riverside, CA, USA

10:36 O-34 SIGNALLING NETWORKS IN THE RAPID ACTION OF ANDROGENS IN MALE OSTEOBLASTS. FROM G BETA 4 TO ELK1 ACTIVATION
Y. Zagar, G. Chaumaz, M. Lieberherr*
LNSA, INRA, Jouy-en-Josas, France

10:48 O-35 OSTEOBLAST-LIKE CELLS FROM ESTROGEN RECEPTOR ALPHA KNOCKOUT (ERKO) MICE HAVE DEFICIENT RESPONSES TO MECHANICAL STRAIN
H. L. Jessop*, R. F. L. Suswillo, S. C. F. Rawlinson, G. Zaman, K. Lee, V. Das-Gupta, A. A. Pitsillides, L. E. Lanyon
Department of Veterinary Basic Sciences, The Royal Veterinary College, London, UK

WORKSHOP 5

INFLAMMATION AND BONE

Chairs: G. Girasole (Genova, Italy)
S. Vukicevic (Zagreb, Croatia)

12:45 I-24 Anti-TNF therapy for rheumatoid arthritis: prospects for the future
M. Feldmann (London, UK)

13:10 I-25 Regulation of bone cell function by pro-inflammatory cytokines
S. R. Goldring (Boston MA, USA)

13:35 I-26 Mechanisms of bone loss in aseptic prosthetic loosening
E. M. Schwarz (New York NY, USA)

CHILDREN’S BONE DISEASES AND DIFFICULT MANAGEMENT PROBLEMS

Chairs: M. L. Bianchi (Milan, Italy)
M. J. Econs (Indianapolis IN, USA)

12:45 I-27 Osteogenesis imperfecta
N. Bishop (Sheffield, UK)

13:10 I-28 Autosomal Dominat Osteopetrosis (ADO). From the patient to the mutation
J. Bollerslev (Oslo, Norway)

13:35 I-29 Skeletal displasias
M. P. Whyte (St Louis MO, USA)

SYMPOSIUM 6

OTHER BONE DISEASES

Chairs: G. Bianchi (Genova, Italy)
M. P. Whyte (St Louis MO, USA)

14:00 I-30 Pathogenesis of hypophosphataemic rickets
M. J. Econs (Indianapolis IN, USA)

14:30 I-31 Recent advances in sclerosing bone dysplasias
Wim Van Hul (Antwerp, Belgium)

METABOLIC BONE DISEASES

Chairs: G. Bianchi (Genova, Italy)
M. P. Whyte (St Louis MO, USA)

15:00 O-36 INTRAVENOUS NERIDRONATE IN ADULTS WITH OSTEOGENESIS IMPERFECTA
F. Colapietro*, S. Adami, R. Prizzi, D. Gatti, V. Braga, D. Gerardi, D. Righetti, M. Rossini
Rheumatological Rehabilitation, University Hospital Valeggio S/M, Italy

15:12 O-37 TREATMENT OF ESTABLISHED GLUCOCORTICOID-INDUCED OSTEOPOROSIS WITH ALFACALCIDOL OR PLAIN VITAMIN D
J. D. Ringe¹*, A. Dorst¹, H. Faber¹, E. Schacht^2
1Klinikum Leverkusen, Medizinische Klinik 4, University of Cologne, Germany
²University Clinic Balgrist, Zurich, Switzerland

15:24 O-38 TRAIL IS EXPRESSED IN QUANTITIES SIMILAR TO RANKL IN HUMAN PERIPROSTHETIC PSEUDOMEMBRANE, OSTEOARTHRITIC STROMAL CELLS AND OSTEOBLASTS
A. Sabokbar¹*, H. C. Blair², S. Sun¹, J. Edwards¹, L. Danks¹, N. A. Athanasou^1
1University of Oxford, UK
²University of Pittsburgh, USA

15:36 O-39 OPG AND CELLULAR GENE THERAPY WITH IL-4 DECREASE BONE RESORPTION-RELATED INFLAMMATION IN COLLAGEN-INDUCED ARTHRITIS
N. Saidenberg-Kermanac'h¹*, N. Bessis¹, M. C. de Vernejoul², M. C. Boissier¹, M. E. Cohen-Solal^2
1EA-3408, University Paris XIII, Bobigny, France
²INSERM U349, Paris, France

15:48 O-40 DEVELOPMENT OF NOVEL DUAL-ACTION SRC KINASE INHIBITORS PREVENTING BONE RESORPTION AND STIMULATING BONE FORMATION IN VITRO AND IN VIVO
B. F. Boyce¹*, L. Xing¹, Y. Wang², R. Sundaramoorthi², T. Keenan², T. Yamashita1¹, W. Shakespeare², D. Dalgarno², J. Iuliucci², T. Sawyer^2
1Department of Pathology, University of Rochester, Rochester, NY, USA
²ARIAD Pharmaceuticals, Cambridge, MA, USA

OSTEOPOROSIS ASSESSMENT & TREATMENT

Chairs: R. Eastell (Sheffield, UK)
R. Nuti (Siena, Italy)

16:20 O-41 WHOM TO TREAT? THE CONTRIBUTION OF VERTEBRAL X-RAYS TO RISK BASED ALGORITHMS FOR PREDICTING NEW SPINE FRACTURES
S. Kaptoge¹*, M. Lunt², D. Felsenberg³, T. W. O'Neill², J. Reeve¹, E. P. O. S. Study Group^1
1Department of Medicine & Institute of Public Health, University of Cambridge, Cambridge, UK
²ARC Epidemiology Unit, University of Manchester, Manchester, UK
³Department of Radiology, Frei University B Franklin, Berlin, Germany

16:32 O-42 PREDICTION OF NON VERTEBRAL FRACTURE RISK BY HEEL ULTRASOUND IN A POPULATION OF 7'585 SWISS WOMEN AGED 70 TO 80 YEARS
M. A. Krieg*, J. Cornuz, C. Ruffieux, P. Burckhardt
University Hosptital, Lausanne, and the SEMOF study group, Switzerland

16:44 O-43 A META-ANALYSIS OF PREVIOUS FRACTURE AND FRACTURE RISK
C. E. De Laet*, P. Delmas, P. Garnero, H. Johansson, O. Johnell, J. A. Kanis, H. Kroger, E. V. McCloskey, D. Mellstrom, J. L. Melton, A. Oden, A. Oglesby, H. Pols, J. Reeve, A. Silman, A. Tenenhouse
Erasmus University Medical Center, Rotterdam, The Netherlands

16:56 O-44 DAILY AND INTERMITTENT ORAL IBANDRONATE PROVIDE SIGNIFICANT REDUCTIONS IN VERTEBRAL FRACTURE RISK: RESULTS FROM A LARGE PHASE III STUDY
P. D. Delmas¹*, C. H. Chesnut III², C. Christiansen³, A. Skag⁴, R. R. Recker⁵, J. A. Stakkestad⁶, A. Hoiseth⁷, D. Felsenberg⁸, P. Mahoney⁹, R. C. Schimmer^9
1Claude Bernard University and INSERM Research Unit 403, Lyon, France
²University of Washington, Seattle, USA
³Center for Clinical and Basic Research, Ballerup Byvej, Denmark
⁴Center for Clinical Trials, Bergen, Norway
⁵Creighton University, Omaha, NE, USA
⁶CECOR AS, Haugesund, Norway
⁷Sentrum Røntgen Institut AS, Oslo, Norway
⁸Universitatsklinikum Benjamin Franklin, Berlin, Germany
⁹F. Hoffmann-La Roche Ltd, Basel, Switzerland

17:08 O-45 TERIPARATIDE REDUCES THE RISK OF VERTEBRAL FRACTURES REGARDLESS OF BASELINE VERTEBRAL FRACTURE NUMBER AND SEVERITY
J. C. Gallagher¹*, S. J. Vargas², G. Crans², G. A. Gaich², B. H. Mitlak^2
1Creighton University, Omaha NE, USA
²Lilly Research Laboratories, Eli Lilly and Company, Indianapolis IN, USA

EMERGING IDEAS IN UNDERSTANDING BISPHOSPHONATE TREATMENT: FROM BASIC RESEARCH TO CLINICAL PRACTICE

Supported by Aventis/P&GP - The Alliance
for Better Bone Health

Chairs: M.L. Brandi, R. Lindsay

17:40 - 17:50 Introduction
M. L. Brandi
(University of Florence, Florence, Italy)

17:50 - 18:10 Are all BPs the same?
Graham Russell
(University of Oxford, Oxford, UK)

18:10 - 18:30 Assessing bone quality
E. Paschalis
(Hospital for Special Surgery, New York, USA)

18:30 - 18:50 Clinical utility of risedronate in the treatment of osteoporosis
S. Boonen
(Center of Metabolic Bone Disease,  Leuven, Belgium)

18:50 - 19:05 Closing remarks
R. Lindsay
(Helen Hayes Hospital, New York, USA)

20:30 GALA DINNER